P62 ligand compound, and composition for preventing, ameliorating or treating proteinopathies comprising the same

A compound, a pharmaceutically acceptable salt, stereoisomer, hydrate, solvate or prodrug thereof, wherein the compound is selected from the group consisting of the following compounds:

• 1) 2-((2-((3,4-bis(benzyloxy)benzyl)amino)ethyl)amino)ethan-1-ol (YTK-1108);
• 2) 1-(2-((3-(benzyloxy)benzyl)amino)ethyl)guanidine (YTK-107);
• 3) 1-(2-((3-(phenethoxybenzyl)amino)ethyl)guanidine (YTK-207);
• 4) 2-(2-((3,4-bis(benzyloxy)benzyl)amino)ethoxy)ethan-1-ol (YTK-11-A76);
• 5) 1-(3,4-bis(benzyloxy)benzyl)-3-(2-hydroxyethyl)urea (ATB10041);
• 6) N-(3,4-bis(benzyloxy)benzyl)-2-hydroxyacetamide (ATB10042);
• and
• 7) (R)-2-amino-3-((3,4-bis(benzyloxy)benzyl)amino)propanoic acid (ATB10043).